Benzinga··Vandana SinghUnited Therapeutics Surges 16.5% on Positive Lung Disease Trial Results
United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial